COPD

The Pharmacy Times® Chronic Obstructive Pulmonary Disease (COPD) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
They can help patients improve inhalation technique, ensuring better medication adherence.


 
[[thumbnail_alt_text]]
Digital health tools were a major theme during the first-ever NASP Challenge, comprising 4 of the 5 finalists.
 
[[thumbnail_alt_text]]
The triple combination therapy is the first single inhaler triple therapy approved for both asthma and COPD and is the only single inhaler triple therapy available as a once-daily inhalation.
[[thumbnail_alt_text]]
Chronic obstructive pulmonary disease may remain undetected due to individuals thinking that the symptoms are a normal sign of aging.
 
[[thumbnail_alt_text]]
Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere, AstraZeneca) has been approved by the FDA for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), according to a press release.
[[thumbnail_alt_text]]
Although COPD often develops as a result of smoking, researchers have long puzzled over why nearly one-third of cases occur in people who never smoked.
 
[[thumbnail_alt_text]]
At the first educational session of PQA, the speakers discussed pharmacists’ roles in influencing outcomes associated with social determinants of health in the US population.
 
[[thumbnail_alt_text]]
During this period, 1834 participants developed lung cancer, of whom 290 had COPD and 1544 did not, according to the researchers.
[[thumbnail_alt_text]]
Over $170 billion in health care spending is attributed to smoking. 
[[thumbnail_alt_text]]
As COPD progresses, patients can experience exacerbations leading to a decreased quality of life and increased costs.
 
[[thumbnail_alt_text]]
Chronic obstructive pulmonary disease (COPD) leads in hospital costs, physician services, and prescription drugs.
[[thumbnail_alt_text]]
Investigators have proposed a tool involving a personalized approach for managing chronic obstructive pulmonary disease (COPD) and the use of inhaled corticosteroids (ICS), according to the results of a recent study published in the International Journal of Chronic Obstructive Pulmonary Disease.